<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620940</url>
  </required_header>
  <id_info>
    <org_study_id>IVL3004-001</org_study_id>
    <nct_id>NCT05620940</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3004</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Exploratory, Parallel, Pharmacokinetic Single Dose Study of IVL3004 Versus Vivitrol® (Naltrexone) LAI in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inventage Lab., Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inventage Lab., Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3004&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, Randomized, Open-Label, Exploratory, Parallel, Pharmacokinetic Single Dose Study&#xD;
      of IVL3004 Versus Vivitrol® (Naltrexone) Long-Acting Injectable in Healthy Subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2023</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 27, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Pre-dose, up to Day 57</time_frame>
    <description>Area under the concentration-time curve from time zero to Day 57</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose, up to Day 57</time_frame>
    <description>The maximal observed concentration</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Opioid Dependence</condition>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Vivitrol Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vivitrol, Single Dose, IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVL3004 (A mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM, Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVL3004 (B mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC, Single Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vivitrol Injectable Product</intervention_name>
    <description>Naltrexone Long-Acting Injection</description>
    <arm_group_label>Vivitrol Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVL3004</intervention_name>
    <description>Naltrexone Long-Acting Injection</description>
    <arm_group_label>IVL3004 (A mg)</arm_group_label>
    <arm_group_label>IVL3004 (B mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male or female, ≥18 and ≤55 years of age, non-smokers&#xD;
&#xD;
          2. BMI ≥18.0 and ≤32.0 kg/m2 and body weight ≥55.0 kg for males and ≥50.0 kg for females.&#xD;
&#xD;
          3. Healthy as defined by:&#xD;
&#xD;
               1. The absence of clinically significant illness, infection, medical/surgical&#xD;
                  procedure, or trauma within 4 weeks prior to dosing, or planned inpatient surgery&#xD;
                  (including dental surgery) or hospitalization during the study period.&#xD;
&#xD;
               2. The absence of clinically significant history of neurological, endocrine,&#xD;
                  cardiovascular, respiratory, hematological, immunological, psychiatric,&#xD;
                  gastrointestinal, renal, hepatic, and metabolic disease.&#xD;
&#xD;
          4. Females of childbearing potential who are sexually active with a male partner must be&#xD;
             willing to use one of the following acceptable contraceptive methods throughout the&#xD;
             study and for 57 days after dosing for subjects in all cohorts.&#xD;
&#xD;
               1. Simultaneous use of hormonal contraceptives started at least 4 weeks prior to&#xD;
                  dosing and condom for the male partner.&#xD;
&#xD;
               2. Simultaneous use of intrauterine device placed at least 4 weeks prior to dosing,&#xD;
                  and condom for the male partner.&#xD;
&#xD;
               3. Sterile male partner (vasectomized since at least 3 months).&#xD;
&#xD;
          5. Females of non-childbearing potential must be:&#xD;
&#xD;
               1. Post-menopausal (spontaneous amenorrhea for at least 12 months prior to dosing)&#xD;
                  with confirmation by documented FSH levels ≥40 mIU/mL; or&#xD;
&#xD;
               2. Surgically sterile (hysterectomy, bilateral oophorectomy, bilateral&#xD;
                  salpingectomy, or tubal ligation) at least 3 months prior to dosing.&#xD;
&#xD;
          6. Male subjects who are not vasectomized for at least 3 months prior to dosing, and who&#xD;
             are sexually active with a female partner of childbearing potential must be willing to&#xD;
             use one of the following acceptable contraceptive methods from dosing and for 90 days&#xD;
             after dosing:&#xD;
&#xD;
             a. Simultaneous use of a male condom and, for the female partner, hormonal&#xD;
             contraceptives used for at least 4 weeks or intrauterine device placed for at least 4&#xD;
             weeks prior to sexual intercourse.&#xD;
&#xD;
          7. Male subjects who are sexually active with a same-sex partner must be willing to use a&#xD;
             condom until study exit.&#xD;
&#xD;
          8. Male and female subjects who practice abstinence from sexual intercourse as a usual&#xD;
             and preferred lifestyle.&#xD;
&#xD;
          9. Male subjects must be willing not to donate sperm for 90 days after dosing.&#xD;
&#xD;
         10. Willing and able to provide written informed consent after the nature of the study has&#xD;
             been explained and prior to the commencement of any protocol specific study&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any clinically significant abnormal finding at physical examination at screening.&#xD;
&#xD;
          2. Clinically significant abnormal laboratory test results or positive serology test&#xD;
             results for HIV, hepatitis B or hepatitis C virus at screening.&#xD;
&#xD;
          3. Positive pregnancy test at screening or Day -1 or lactating female subject.&#xD;
&#xD;
          4. Positive drug or alcohol screen at screening or Day -1.&#xD;
&#xD;
          5. Any history of malignancy or neoplastic disease.&#xD;
&#xD;
          6. History of significant allergic reactions (e.g., drug reaction, anaphylactic reaction,&#xD;
             hypersensitivity, angioedema) to naltrexone or other related drugs, or to any&#xD;
             excipient present in the formulation for any study drug.&#xD;
&#xD;
          7. ALT, AST or total bilirubin &gt;1.5x ULN at screening or Day -1.&#xD;
&#xD;
          8. Estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73m2 as calculated by the&#xD;
             2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) equation at screening or Day -1.&#xD;
&#xD;
          9. Clinically significant ECG abnormalities (QTc &gt;450 ms or PR interval &gt;220 ms) or vital&#xD;
             sign abnormalities (systolic blood pressure &lt;90 or &gt;140 mmHg, diastolic blood pressure&#xD;
             &lt;40 or &gt;90 mmHg, or heart rate &lt;50 or &gt;100 bpm) at screening or Day -1.&#xD;
&#xD;
         10. History of significant bradycardia or AV block.&#xD;
&#xD;
         11. History of alcohol abuse within 1 year prior to screening or regular use of alcohol&#xD;
             within 6 months prior to screening that exceeds 14 units of alcohol per week (1 unit =&#xD;
             375 mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of spirit 40%).&#xD;
&#xD;
         12. History of drug abuse within 1 year prior to screening or recreational use of soft&#xD;
             drugs (such as marijuana) or hard drugs (such as cocaine, PCP, crack, opioid&#xD;
             derivatives including heroin, and amphetamine derivatives) within 1 month, or use of&#xD;
             codeine within 3 months prior to screening.&#xD;
&#xD;
         13. Use of medications for the timeframes specified below, with the exception of hormonal&#xD;
             contraceptives and medications exempted by the Investigator on a case-by-case basis&#xD;
             because they are judged unlikely to affect the PK profile of the study drug or subject&#xD;
             safety (e.g., topical drug products without significant systemic absorption):&#xD;
&#xD;
               1. Depot injection or implant within 3 months prior to dosing;&#xD;
&#xD;
               2. Any drug known to induce or inhibit hepatic metabolism within 30 days prior to&#xD;
                  dosing;&#xD;
&#xD;
               3. Prescription medications within 14 days prior to dosing;&#xD;
&#xD;
               4. Any vaccine, including COVID-19 vaccine, within 7 days prior to dosing;&#xD;
&#xD;
               5. OTC medications within 7 days prior to dosing, except for occasional use of&#xD;
                  acetaminophen/paracetamol (up to 2 g/day), and topical formulations without&#xD;
                  significant systemic absorption.&#xD;
&#xD;
               6. Natural health products (including herbal remedies, homeopathic and traditional&#xD;
                  medicines, probiotics, food supplements such as vitamins, minerals, amino acids,&#xD;
                  essential fatty acids, and protein supplements used in sports) within 7 days&#xD;
                  prior to dosing;&#xD;
&#xD;
               7. Anesthetic agents within 24 hours prior to dosing.&#xD;
&#xD;
         14. Participation in a clinical research study involving the administration of an&#xD;
             investigational or marketed drug or device within 30 days prior to dosing,&#xD;
             administration of a biological product in the context of a clinical research study&#xD;
             within 90 days prior to dosing, or concomitant participation in an investigational&#xD;
             study involving no drug or device administration.&#xD;
&#xD;
         15. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more&#xD;
             of whole blood within 30 days prior to dosing.&#xD;
&#xD;
         16. Any reason which, in the opinion of the Investigator, would prevent the subject from&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Betty Geum</last_name>
    <phone>82-31-608-0514</phone>
    <phone_ext>5571</phone_ext>
    <email>betty.geum@inventagelab.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuna Chae</last_name>
    <phone>82-31-608-0514</phone>
    <phone_ext>5135</phone_ext>
    <email>yuna.chae@inventagelab.com</email>
  </overall_contact_backup>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

